Go Pro
→ The options guide that actually starts at the beginning (From Base Camp Trading) (Ad)tc pixel Free SBTX Stock Alerts

SkinBioTherapeutics (SBTX) Competitors

SkinBioTherapeutics logo
GBX 11.15 +0.65 (+6.19%)
As of 07/21/2026 11:44 AM Eastern
Compare

SBTX vs. MPH, FARN, BVXP, 4BB, and ORPH

Should you buy SkinBioTherapeutics stock or one of its competitors? MarketBeat compares SkinBioTherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SkinBioTherapeutics include Mereo BioPharma Group plc (MPH.L) (MPH), Faron Pharmaceuticals Oy (FARN), Bioventix (BVXP), 4basebio (4BB), and Open Orphan (ORPH). These companies are all part of the "biotechnology" industry.

How does SkinBioTherapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

3.0% of SkinBioTherapeutics shares are owned by institutional investors. 2.7% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Mereo BioPharma Group plc (MPH.L) has higher earnings, but lower revenue than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
SkinBioTherapeutics£5.23M5.53-£3.71M-£0.16N/A

In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
SkinBioTherapeutics Neutral

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
SkinBioTherapeutics -8.73%-5.25%-61.18%

Summary

Mereo BioPharma Group plc (MPH.L) and SkinBioTherapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for SkinBioTherapeutics. Faron Pharmaceuticals Oy's average media sentiment score of 0.75 beat SkinBioTherapeutics' score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company Overall Sentiment
Faron Pharmaceuticals Oy Positive
SkinBioTherapeutics Neutral

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 45.13% -70.00%
SkinBioTherapeutics -8.73%-5.25%-61.18%

Faron Pharmaceuticals Oy has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.107, suggesting that its share price is 89% less volatile than the broader market.

SkinBioTherapeutics has higher revenue and earnings than Faron Pharmaceuticals Oy. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A
SkinBioTherapeutics£5.23M5.53-£3.71M-£0.16N/A

2.5% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 3.0% of SkinBioTherapeutics shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Faron Pharmaceuticals Oy beats SkinBioTherapeutics on 7 of the 12 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Bioventix?

SkinBioTherapeutics (LON:SBTX) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

3.0% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bioventix has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£5.23M5.53-£3.71M-£0.16N/A
Bioventix£12.54M6.38£8.12M£140.5210.90

Bioventix has a net margin of 59.30% compared to SkinBioTherapeutics' net margin of -8.73%. Bioventix's return on equity of 65.83% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
Bioventix 59.30%65.83%54.07%

SkinBioTherapeutics has a beta of 0.107, suggesting that its share price is 89% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.554, suggesting that its share price is 45% less volatile than the broader market.

In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company Overall Sentiment
SkinBioTherapeutics Neutral
Bioventix Neutral

Summary

Bioventix beats SkinBioTherapeutics on 11 of the 11 factors compared between the two stocks.

How does SkinBioTherapeutics compare to 4basebio?

SkinBioTherapeutics (LON:SBTX) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

4basebio has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
4basebio N/A -231.29%-54.30%

SkinBioTherapeutics has a beta of 0.107, suggesting that its share price is 89% less volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

4basebio has a consensus price target of GBX 1,400, suggesting a potential upside of 180.00%. Given 4basebio's stronger consensus rating and higher probable upside, analysts clearly believe 4basebio is more favorable than SkinBioTherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SkinBioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company Overall Sentiment
SkinBioTherapeutics Neutral
4basebio Neutral

3.0% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 0.9% of 4basebio shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by insiders. Comparatively, 12.1% of 4basebio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

SkinBioTherapeutics has higher revenue and earnings than 4basebio. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£5.23M5.53-£3.71M-£0.16N/A
4basebio£1.69M45.73-£9.84M-£109.00N/A

Summary

4basebio beats SkinBioTherapeutics on 9 of the 14 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Open Orphan?

SkinBioTherapeutics (LON:SBTX) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Open Orphan has higher revenue and earnings than SkinBioTherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£5.23M5.53-£3.71M-£0.16N/A
Open Orphan£34.71M0.00N/AN/AN/A

Open Orphan has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Open Orphan's return on equity of 0.00% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
Open Orphan N/A N/A N/A

3.0% of SkinBioTherapeutics shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled Open Orphan'saverage media sentiment score.

Company Overall Sentiment
SkinBioTherapeutics Neutral
Open Orphan Neutral

Summary

Open Orphan beats SkinBioTherapeutics on 5 of the 7 factors compared between the two stocks.

Get SkinBioTherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBTX vs. The Competition

Export
MetricSkinBioTherapeuticsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£28.90M£444.73M£6.81B£2.79B
Dividend YieldN/A3.90%2.67%6.16%
P/E Ratio-69.693.4926.97368.25
Price / Sales5.536,249.84507.3984,392.87
Price / Cash9.0013.1349.7127.89
Price / Book6.6487.6810.677.59
Net Income-£3.71M-£96.07M£3.60B£5.89B
7 Day Performance17.37%-0.27%-0.99%0.16%
1 Month Performance-0.45%0.35%1.60%-0.87%
1 Year Performance-33.43%57.77%24.14%62.65%

SkinBioTherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBTX
SkinBioTherapeutics
N/AGBX 11.15
+6.2%		N/A-33.0%£28.90M£5.23MN/A11
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50
FARN
Faron Pharmaceuticals Oy
N/AGBX 41.62
+0.3%		N/A-79.4%£84.44MN/AN/A34
BVXP
Bioventix
N/AGBX 1,580
-1.3%		N/A-43.3%£82.56M£12.54M11.2412
4BB
4basebio
N/AGBX 550
+4.8%		GBX 1,400
+154.5%		-47.4%£81.30M£1.69MN/A101

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SBTX) was last updated on 7/22/2026 by MarketBeat.com Staff.
From Our Partners
The options guide that actually starts at the beginning
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
30-Year market veteran reveals America’s #1 Stock
Market veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...
Eagle Publishing | Sponsoredtc pixel
The SpaceX IPO Wasn't For You
Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...
Freedom Financial | Sponsoredtc pixel
Not oil. Not solar. Bigger.
The International Energy Agency measured it at 140 times global electricity demand. It runs 24 hours a day, pr...
Behind the Markets | Sponsoredtc pixel